Skip to content

Post-Market Clinical Follow-Up Study on the Safety and Performance of Ennovate® Complex

Multicenter Post Market Clinical Follow-Up (PMCF) Study on the Safety and Performance of Ennovate® Complex - A Prospective Study on Scoliosis Patients

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05281757
Acronym
COSINE
Enrollment
200
Registered
2022-03-16
Start date
2022-02-18
Completion date
2028-10-01
Last updated
2026-06-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Congenital Scoliosis, Hyperkyphosis, Hyperlordosis, Idiopathic Scoliosis, Neuromuscular Scoliosis

Keywords

upper-thoracic spine

Brief summary

Multicenter, multinational Post-Market Clinical Follow-Up (PMCF) study on the safety and performance of Ennovate® Complex - A prospective, pure data collection of all Ennovate® scoliosis patients in selected centers (not interventional, multicentric)

Detailed description

This clinical study is one of the Post-Market Clinical Follow-Up (PMCF) measures that enables the manufacturer to monitor the clinical safety and performance of the Ennovate® Complex system. The study enables a quick, but detailed implant documentation, which is of great interest for the current and future users of the internal fixation system targeted in this study. It includes the relevant outcomes to evaluate safety and efficacy of the implant system for various indications in deformity disorders.

Interventions

The Ennovate® Complex Spinal System is a posterior stabilization for the Complex and upper-thoracic spine. The implants are used for the posterior multisegmental correction and stabilization over all sections of the spine.

Sponsors

Aesculap AG
Lead SponsorINDUSTRY
Raylytic GmbH
CollaboratorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Informed consent in the documentation of clinical and radiological results of patients who are minimum 18 years old * Informed consent in the documentation of clinical and radiological results of patients AND legal representative (parent) for patients who are younger than 18 * Patient's indication according to IFU * Patient is not pregnant

Exclusion criteria

* Patient's clear unability or unwillingness to participate in follow-up examinations

Design outcomes

Primary

MeasureTime frameDescription
Change of Painpreoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperativelyain will be assessed by the patient using the Visual Analogue Scale (VAS) which state "0" at one end representing "no pain" and "100" at the opposite end representing "maximal / worst pain".

Secondary

MeasureTime frameDescription
Change of Quality of Lifepreoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperativelyIn order to analyze the quality of life of the patients, the most current questionnaire of the Scoliosis Research Society (SRS), the "SRS-30" is used. The SRS-30 demonstrates how spinal conditions impact quality of life and facilitate comparisons of the quality of life before and after surgical intervention. It is widely used in the evaluation of the treatment of idiopathic scoliosis patients. SRS-30 is a patient self administered questionnaire and has a minimum score of 30 and a maximum score of 150 including postsurgery questions. Each question is scored on 1-5 scale. Questions are sorted into different domains and total and mean scores for each domain are calculated. A total score for the entire questionnaire is also calculated.
Change of Every day lifepreoperatively, at 3-4 months postoperatively and at approximately 12 and 24 months postoperativelyClinical Results measured by Oswestry Disability Index (ODI). ODI contains ten topics concerning intensity of pain, lifting, ability to care for oneself, ability to walk, ability to sit, sexual function, ability to stand, social life, sleep quality, and ability to travel, each topic category is followed by 6 statements describing different potential scenarios in the patient's life relating to the topic. Each question is scored on a scale of 0 (indicating the least amount of disability) to 5 5 (indicating most severe disability). The scores for all questions answered are summed, then multiplied by two to obtain the index (range 0 to 100). Zero is equated with no disability and 100 is the maximum disability possible.
Bone Fusionat final follow-up approximately 24 months after surgeryAfter Complex stabilization fusion of the treated segment is aspired in most cases. The fusion status can be determined from radiographs (static or dynamic). Bony fusion can be characterized quantitatively by the fusion rate.
Cumulative number of Side effectsthroughout the follow-up up to 24 months postoperativelyOccurrence of complications potentially associated with the implanted devices can never be fully excluded during spinal surgery. In order to monitor potential complication and to identify so far unknown complications Adverse Events and Serious Adverse Events deemed related to the investigational device are recorded.

Countries

Czechia, Malaysia

Contacts

CONTACTSarah Mattes
sarah.mattes@aesculap.de+497461950
CONTACTStefan Maenz
stefan.maenz@aesculap.de+497461950
PRINCIPAL_INVESTIGATORMohd Hisam, Prof. Dr.

Hospital Universiti Kebangsaan Malaysia (HUKM)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 3, 2026